financetom
Business
financetom
/
Business
/
Lumen Technologies shares extend AI-fueled surge after rosy cash-flow outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lumen Technologies shares extend AI-fueled surge after rosy cash-flow outlook
Aug 7, 2024 12:24 PM

NEW YORK (Reuters) - Shares of Lumen Technologies ( LUMN ) surged 30% on Wednesday, extending gains from the previous session, after the telecommunications company boosted its annual free-cash-flow forecast due to demand related to artificial intelligence.

Lumen shares were trading at $6.54 per share after hitting an intra-day high of $7.83, which is the highest since October 2022. The stock nearly doubled on Tuesday, soaring 93% to close at $5 from $2.59. It is now up 256% this year.

The company announced on Monday it had secured new deals worth $5 billion from cloud and technology companies, including Microsoft, for its networking and cybersecurity equipment as more businesses adopt AI-driven computing.

As a result, Lumen reported on Tuesday that it expects annual free cash flow to jump to between $1 billion and $1.2 billion, from between $100 million and $300 million.

JPMorgan analysts upgraded Lumen to "neutral" from "underweight." Other analysts, including from TD Cowen, raised their price targets.

Among the 12 analysts who cover Lumen, their median price target is $1.75 and their average rating is "hold", according to LSEG data. Lumen, which has a market value of about $6.8 billion, has a forward price-earnings ratio of minus-40.17, per LSEG data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Alumis Shares Tuesday?
What's Going On With Alumis Shares Tuesday?
Mar 25, 2025
Alumis, Inc. ( ALMS ) stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. What To Know: Under the agreement, Alumis ( ALMS ) is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for development, manufacturing and commercialization in Japan, limited to...
Organovo Completes Sale of FXR Program to Eli Lilly
Organovo Completes Sale of FXR Program to Eli Lilly
Mar 25, 2025
11:52 AM EDT, 03/25/2025 (MT Newswires) -- Organovo ( ONVO ) said Tuesday that it has completed the sale of its farnesoid X receptor, or FXR, program to Eli Lilly ( LLY ) . The agreement was announced in February, with Organovo ( ONVO ) saying it will sell the FXR program for an upfront payment of $10 million and...
What's Going On With Predictive Oncology Shares Tuesday?
What's Going On With Predictive Oncology Shares Tuesday?
Mar 25, 2025
Predictive Oncology, Inc. ( POAI ) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were developed using 21 unique compounds from the University of Michigan's Natural Products Discovery Core, which were tested for their effectiveness against cancers such as breast, colon and ovarian. The collaboration...
Signal head defends messaging app's security after US war plan leak
Signal head defends messaging app's security after US war plan leak
Mar 25, 2025
LONDON, March 25 (Reuters) - The president of Signal defended the messaging app's security on Wednesday after top Trump administration officials mistakenly included a journalist in an encrypted chatroom they used to discuss a looming U.S. attack on Yemen's Houthis. Signal's Meredith Whittaker did not directly address the blunder, which Democratic lawmakers have said was a breach of U.S. national...
Copyright 2023-2026 - www.financetom.com All Rights Reserved